GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (LSE:AGL) » Definitions » Float Percentage Of Total Shares Outstanding

ANGLE (LSE:AGL) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 08, 2024)


View and export this data going back to 2004. Start your Free Trial

What is ANGLE Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ANGLE's float shares is 0.00 Mil. ANGLE's total shares outstanding is 261.00 Mil. ANGLE's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ANGLE's Insider Ownership is 3.35%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ANGLE's Institutional Ownership is 7.15%.


ANGLE Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ANGLE's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/261.00
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ANGLE (LSE:AGL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (LSE:AGL) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
ANGLE PLC is active in the healthcare sector in the United Kingdom. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which majority of its revenue is generated from Europe.